Medicxi

What they fund

• Stage: Primarily Series A and Series B, with some growth-stage investments [2].
• Sector: Life Sciences, Biotechnology, and HealthTech, with a strong emphasis on oncology [1].
• Geography: United States, United Kingdom, and broader Europe [2].
• Shape: Companies built around specific drug candidates or platforms, often involving tranched investments [1].
• Deal Size: Up to $38 million in tranched investments for specific drug development programs [1].

Investment thesis

Medicxi operates on an asset-centric model, building new companies around specific experimental drug candidates rather than funding broad, unproven drug-making platforms [1]. This approach aims to de-risk development by focusing on high-conviction, specific assets [1]. The firm leverages its institutional pedigree, backed by giants like GSK and Johnson & Johnson, to align with deep industry credibility and strategic partners [1]. By converting development candidates into high-value commercial assets, Medicxi targets unmet medical needs, particularly in oncology and rare diseases [1].

Credibility: The asset-centric model and tranched investment structure are detailed in the Starpharma partnership announcement [1]. The institutional backing and strategic focus are confirmed by the firm's public profile and partnership details [1].

Value add

Medicxi provides strategic partnerships and access to industry experts, as seen in the appointment of Dr. Mehdi Shahidi as CEO of Petalion Therapeutics [1]. They offer tranched investment plans that allow for staged funding based on milestones [1]. Their institutional backing provides credibility and potential strategic alliances with major pharma [1].

Fit verdict: Ideal for biotech founders needing staged funding and strategic industry connections.

Founder diligence script:

• What specific milestones trigger the next tranche of funding?
• How does Medicxi leverage its GSK and J&J relationships for our asset?
• What is the expected timeline for converting our candidate into a commercial asset?
• How does Medicxi handle co-investment with Orbimed and other partners?

Portfolio focus

• Ultrahuman: Wearable health trackers and metabolic monitoring devices, focusing on consumer health tech [2].
• Adaptive Biotechnologies: Clinical diagnostics and drug discovery for immune diseases, now a public company [2].
• Evotec: AI-driven life science company accelerating drug discovery and preclinical development [2].
• Acutus Medical: Developer of ablation products for cardiac arrhythmias, now public [2].
• Petalion Therapeutics: UK-based oncology company focused on dendrimer-drug conjugates, co-founded with Starpharma [1].

Notable investments & exits

• Adaptive Biotechnologies: IPO, demonstrating success in taking portfolio companies public [2].
• Evotec: Public company, showing ability to scale and exit via IPO [2].
• Acutus Medical: Public company, highlighting success in medical device exits [2].
• Centessa Pharmaceuticals: Acquisition, indicating successful exit via M&A [2].
• RAPT Therapeutics: Acquisition, further evidence of M&A exit capability [2].

Strategic implications

Medicxi's asset-centric model reduces risk by focusing on specific drug candidates, making it a reliable partner for biotech startups with promising assets. The firm's institutional backing from GSK and J&J provides a strategic advantage in navigating the complex regulatory and commercial landscape of life sciences. The consistent history of IPOs and acquisitions suggests Medicxi has a proven track record of scaling companies, which is a significant signal for founders seeking long-term value creation.

Where they could go further

Medicxi could expand its focus to include more early-stage pre-seed investments to capture assets earlier in the development pipeline. Increasing investments in non-oncology therapeutic areas, such as rare diseases or neurodegenerative disorders, could diversify the portfolio and reduce sector-specific risk. Enhancing support for commercialization and market access strategies could further de-risk the path to exit for portfolio companies. Building a more robust network of co-investors beyond Orbimed could provide additional capital and strategic resources for portfolio companies.